Carmen Ballesteros-Merino

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Background Immunotherapies have improved patient responses and survival , though not all patients benefit. Effective biomarkers may help to improve outcomes. Durvalumab is a human IgG1 mono-clonal antibody that inhibits PD-L1 binding to PD-1 and CD80, restoring antitumor immunity [1, 2]. PD-L1 expression on tumor or tumor-infiltrating immune cells measured(More)
Lung cancer is currently the most common cause of cancer related death in the world and approximately 85% of all lung cancers are non-small cell lung cancer (NSCLC). Previous studies have shown that patients with NSCLC containing high densities of CD8+ memory T cells have a survival advantage. Others have identified an association between relatively high(More)
  • 1